Agios Pharma Offers Updated Data From Phase 1 Dose-Escalation Study Of AG-881 In Patients With IDH Mutant Positive Advanced Glioma: Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining